The study focuses on people born with a blood‑clotting disorder called Congenital hemophilia A, which can cause bleeding into joints and lead to inflammation of the joint lining known as synovitis. The medication being tested is a replacement factor called efanesoctocog alfa, given by intravenous injection to raise the blood’s clotting factor level.
The purpose of the study is to see whether giving a higher amount of this replacement therapy can reduce or eliminate the signs of synovitis over a year. Participants will receive regular infusions of the medicine, will have periodic checks of joint health using ultrasound imaging, and will be followed for about 12 months to record any bleeding events and any side effects.
Throughout the trial, safety will be monitored by recording any adverse events, and the amount of clotting factor in the blood will be measured to understand how long therapeutic levels are maintained. The study will collect information on how often bleeding occurs in joints and the overall number of bleeds, as well as whether the joint inflammation improves.
Austria 
Germany 
